Cosmetic Peptide Matrix
A comprehensive side-by-side comparison of all five major cosmetic peptides covered in the AMP Peptide Research Database: GHK-Cu, Matrixyl, Argireline, Matrixyl 3000, and SNAP-8.
Overview
| Feature |
GHK-Cu |
Matrixyl |
Argireline |
Matrixyl 3000 |
SNAP-8 |
| INCI Name |
Copper Tripeptide-1 |
Palmitoyl Pentapeptide-4 |
Acetyl Hexapeptide-8 |
Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7 |
Acetyl Octapeptide-3 |
| Class |
Copper-binding signal peptide |
Matrikine (signal peptide) |
Neuromodulatory peptide |
Dual matrikine |
Neuromodulatory peptide |
| Primary Function |
Dermal remodeling, collagen synthesis |
Collagen production |
Wrinkle reduction research (muscle relaxation) |
Collagen + anti-inflammatory |
Advanced wrinkle reduction |
| Mechanism |
Copper delivery + TGF-β signaling |
Procollagen fragment mimic |
SNARE complex inhibition |
Matrikine + IL-6 suppression |
Enhanced SNARE inhibition |
| Year Introduced |
~1980s |
~2000 |
~2002 |
~2007 |
~2009 |
| Developer |
Pickart (natural) |
Sederma |
Lipotec |
Sederma/Ashland |
Lipotec |
Chemical Profile Comparison
| Property |
GHK-Cu |
Matrixyl |
Argireline |
Matrixyl 3000 (T1 + T7) |
SNAP-8 |
| CAS Number |
89030-95-5 |
214047-00-4 |
616204-22-9 |
147732-56-7 / 221227-05-0 |
868802-72-6 |
| Sequence |
GHK |
Pal-KTTKS |
Ac-EEMQRR-NH₂ |
Pal-GHK + Pal-GQPR |
Ac-EEMQRRAD-NH₂ |
| Sequence Length |
3 |
5 |
6 |
3 + 4 |
8 |
| Molecular Weight (Da) |
466.4 (complex) |
802.1 |
888.5 |
673.8 + 520.7 |
1074.3 |
| logP |
−2.5 |
3.8 |
−1.7 |
4.0 / 3.8 |
−1.9 |
| Molecular Formula |
C₁₄H₂₄N₆O₄·Cu |
C₃₉H₇₅N₇O₁₀ |
C₃₄H₆₀N₁₄O₁₂S |
C₃₀H₅₃N₇O₆ + C₃₀H₅₂N₈O₇ |
C₄₃H₇₃N₁₅O₁₆S |
| Purity (HPLC) |
≥ 98% |
≥ 98% |
≥ 98% |
≥ 95% |
≥ 98% |
| Lipophilic Modification |
None (copper coordination) |
Palmitoylated (C16) |
N-acetyl + C-amide |
Palmitoylated (C16) |
N-acetyl + C-amide |
Mechanism Comparison
| Mechanism |
GHK-Cu |
Matrixyl |
Argireline |
Matrixyl 3000 |
SNAP-8 |
| Collagen Synthesis |
✓ Strong (TGF-β) |
✓ Strong (matrikine) |
✗ |
✓ Strong (dual matrikine) |
✗ |
| Copper Delivery |
✓ Direct |
✗ |
✗ |
✗ (Pal-GHK only) |
✗ |
| Antioxidant |
✓ Direct + indirect |
✗ |
✗ |
✗ |
✗ |
| Anti-Inflammatory |
✓ (NF-κB) |
✗ |
✗ |
✓ Strong (IL-6) |
✗ |
| SNARE Inhibition |
✗ |
✗ |
✓ Moderate |
✗ |
✓ Strong |
| Muscle Relaxation |
✗ |
✗ |
✓ 30–45% |
✗ |
✓ 30–50% |
| Dermal Remodeling |
✓ Strong |
✗ |
✗ |
✗ |
✗ |
| ECM Remodeling |
✓ (GAGs, decorin) |
✓ (elastin, fibronectin) |
✗ |
✓ (comprehensive) |
✗ |
Research Evidence Comparison
In Vitro Efficacy
| Endpoint |
GHK-Cu |
Matrixyl |
Argireline |
Matrixyl 3000 |
SNAP-8 |
| Collagen I Increase |
70% (1 µM) |
117% (10 µM) |
N/A |
180% (blend) |
N/A |
| Collagen III Increase |
65% |
86% |
N/A |
150% |
N/A |
| Elastin Increase |
50% |
140% |
N/A |
100% |
N/A |
| SNARE Inhibition (IC50) |
N/A |
N/A |
~10 µM |
N/A |
~2 µM |
| Muscle Contraction Reduction |
N/A |
N/A |
30–45% |
N/A |
30–50% |
| IL-6 Suppression |
30% |
10% |
N/A |
65% |
N/A |
Clinical Outcomes
| Endpoint |
GHK-Cu |
Matrixyl |
Argireline |
Matrixyl 3000 |
SNAP-8 |
| Wrinkle Reduction |
35% (fine lines) |
27–38% |
48.9% (roughness) |
70% (volume) |
42% (severity) |
| Skin Firmness |
18% |
18% |
N/A |
32% |
N/A |
| Study Duration |
8–12 weeks |
8–12 weeks |
4–12 weeks |
8–16 weeks |
4–12 weeks |
| Typical Concentration |
0.5–2% |
3% |
5–10% |
3–5% |
5–10% |
Physicochemical Comparison
| Property |
GHK-Cu |
Matrixyl |
Argireline |
Matrixyl 3000 |
SNAP-8 |
| Solubility in Water |
> 50 mg/mL |
< 1 mg/mL |
> 50 mg/mL |
< 1 mg/mL |
> 50 mg/mL |
| Solubility in DMSO |
10–20 mg/mL |
> 50 mg/mL |
> 50 mg/mL |
> 50 mg/mL |
> 50 mg/mL |
| Optimal pH Range |
5.5–6.5 |
5.0–7.0 |
5.0–7.0 |
5.0–7.0 |
5.0–7.0 |
| Solution Stability (4°C) |
7 days |
7 days |
7–14 days |
7 days |
7–14 days |
| Formulation Stability |
12 mo (with antioxidant) |
12+ mo |
12+ mo |
12+ mo |
12+ mo |
| Isoelectric Point (pI) |
~7.5 |
~9.8 |
~10.8 |
~8.5 (mean) |
~8.5 |
| Net Charge at pH 7 |
0 (zwitterion + Cu) |
+2 |
+2 |
+1 (T1), +1 (T7) |
+1 |
Penetration & Delivery Comparison
| Parameter |
GHK-Cu |
Matrixyl |
Argireline |
Matrixyl 3000 |
SNAP-8 |
| logP |
−2.5 (hydrophilic) |
3.8 (lipophilic) |
−1.7 (hydrophilic) |
4.0/3.8 (lipophilic) |
−1.9 (hydrophilic) |
| MW |
466 Da |
802 Da |
889 Da |
674 + 521 Da |
1074 Da |
| Predicted Absorption |
Low |
Moderate |
Low |
Moderate |
Low |
| Penetration Enhancer |
Required |
Not required |
Required |
Not required |
Required |
| Recommended Formulation |
Liposomal |
O/W emulsion |
Liposomal |
O/W emulsion |
Liposomal |
Safety Comparison
| Parameter |
GHK-Cu |
Matrixyl |
Argireline |
Matrixyl 3000 |
SNAP-8 |
| Dermal Irritation |
Non-irritant (5%) |
Non-irritant (5%) |
Non-irritant (10%) |
Non-irritant (8%) |
Non-irritant (10%) |
| Ocular Irritation |
Mild transient |
Mild (concentrated) |
Non-irritant |
Mild transient |
Non-irritant |
| Sensitization |
Non-sensitizing |
Non-sensitizing |
Non-sensitizing |
Non-sensitizing |
Non-sensitizing |
| Mutagenicity |
Negative |
Negative |
Negative |
Negative |
Negative |
| INCI Status |
Approved |
Approved |
Approved |
Approved |
Approved |
Selection Guide
Choose GHK-Cu when:
- Research requires copper-dependent enzymatic activation
- Tissue remodeling, antioxidant, or tissue regeneration endpoints
- Studying TGF-β-mediated collagen synthesis
- Combination approaches with other signal peptides
Choose Matrixyl when:
- Pure matrikine collagen stimulation is the research focus
- Lipophilic formulation compatibility is preferred
- Single-peptide mechanism studies are desired
- Comparing palmitoylated vs non-palmitoylated delivery
Choose Argireline when:
- Neuromodulatory effects on dynamic wrinkles are the endpoint
- Comparison with SNAP-8 for SNARE inhibition studies
- Studying acetylcholine release modulation
- Cost-effective neuropeptide research needed
Choose Matrixyl 3000 when:
- Combined collagen synthesis + anti-inflammatory endpoints
- Comprehensive ECM remodeling studies
- Maximizing anti-aging efficacy in a single formulation
- Clinical-style formulation development
Choose SNAP-8 when:
- Maximum SNARE complex inhibition is required
- Enhanced muscle relaxation compared to Argireline
- Studying structure-activity relationships in neuropeptides
- Advanced wrinkle reduction research
Combination Potential
| Combination |
Synergy |
Rationale |
Evidence |
| GHK-Cu + Matrixyl |
✓ High |
TGF-β + matrikine = amplified collagen |
Preclinical |
| Argireline + Matrixyl 3000 |
✓ High |
Neuromodulation + collagen/anti-inflammatory |
Clinical |
| SNAP-8 + Matrixyl 3000 |
✓ High |
Enhanced neuromodulation + comprehensive ECM |
Proposed |
| GHK-Cu + Argireline |
✓ Moderate |
Dermal remodeling + wrinkle reduction |
Clinical |
| Matrixyl + Matrixyl 3000 |
⚠ Redundant |
Overlapping matrikine mechanisms |
Not recommended |
References
-
Pickart L, et al. (2015). GHK-Cu peptide. Oxygen Transport to Tissue XXXVII. DOI: 10.1007/978-3-319-19096-9_32
-
Robinson LR, et al. (2005). Topical palmitoyl pentapeptide. Journal of Cosmetic Science. DOI: 10.1111/j.1467-2494.2005.00261.x
-
Blanes-Mira C, et al. (2002). A synthetic hexapeptide with antiwrinkle activity. International Journal of Cosmetic Science. DOI: 10.1111/j.1467-2494.2002.00139.x
-
Zhang L, et al. (2009). Anti-wrinkle efficacy of matrikine-based peptides. Biomaterials. DOI: 10.1016/j.biomaterials.2009.07.043
-
Gorouhi F, Maibach HI. (2009). Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science. DOI: 10.1111/j.1468-2494.2009.00497.x
-
Lupo MP, et al. (2007). Cosmeceutical peptides. Dermatologic Therapy. DOI: 10.1111/j.1529-8019.2007.00147.x
-
Lintner K, et al. (2004). Peptide-based anti-aging formulations. Cosmetics & Toiletries. DOI: 10.1111/j.1467-2494.2004.00258.x
🔗 AMP Peptide Product Link
View cosmetic peptide product list at AMP Peptide